

Reference:	FOI.19141.25
Subject:	Multiple Myeloma
Date of Request:	17 December 2025

Requested:

1. Over the past 6 months, how many adult multiple myeloma [MM] patients have you treated? If you refer your multiple myeloma patients to another centre, please state which.

2. Of the multiple myeloma patients over the past 6 months, how many were treated with the following:
 - Belantamab Mafodotin [Blenrep]
 - Belantamab Mafodotin [Blenrep] + Bortezomib [Velcade] + Dexamethasone
 - Belantamab Mafodotin [Blenrep] + Pomalidomide [Imnovid] + Dexamethasone
 - Bortezomib [Velcade] ± Dexamethasone
 - Bortezomib [Velcade] + Melphalan + Prednisolone/Dexamethasone (VMp or VCd)
 - Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)
 - Carfilzomib [Kyprolis] + Dexamethasone
 - Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)
 - Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)
 - Daratumumab [Darzalex] monotherapy
 - Elranatamab
 - Idecabtagene vicleucef [Abecma]
 - Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)
 - Isatuximab [Sarclisa] + Pomalidomide [Imnovid] + Dexamethasone (IsaPd)
 - Ixazomib [Ninlaro] + Lenalidomide [Revlimid] + Dexamethasone (IRd)
 - Lenalidomide [Revlimid] + Dexamethasone
 - Lenalidomide [Revlimid] monotherapy
 - Panobinostat + Bortezomib + Dexamethasone
 - Pomalidomide [Imnovid] + Dexamethasone
 - Selinexor + Bortezomib [Velcade] + Dexamethasone
 - Selinexor + Dexamethasone
 - Talquetamab
 - Teclistamab [Tecvayli]
 - Any other systemic anti-cancer therapy [please specify]

3. In the last 6 months, how many patients have been initiated* on the following regimens?
 - Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)
 - Carfilzomib [Kyprolis] + Dexamethasone
 - Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd)
 - Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)

- Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)
- Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)
- Lenalidomide [Revlimid] monotherapy
- Lenalidomide [Revlimid] + Dexamethasone
- Selinexor + Bortezomib [Velcade] + Dexamethasone
- Selinexor + Dexamethasone
- Any other systemic anti-cancer therapy [please specify]

*Patients are considered initiated if they have not received any of the drugs in the named regimen (either alone or in combination) during the calendar year 2025 prior to initiation.

4. In the last 6 months, how many patients have received the following second-line treatment?
Lenalidomide [Revlimid] + Dexamethasone

Response:

Hywel Dda University Health Board (UHB) is unable to provide you with the exact number of patients for questions 2 and 3 due to the low number (less than 5) and have therefore, replaced the figures in the table with an asterisk (*), as there is a potential risk of identifying individuals if this was disclosed. The UHB is therefore withholding this detail under Section 40(2) of the Freedom of Information Act. This information is protected by the Data Protection Act 2018 (DPA)/UK General Data Protection Regulations (UK GDPR) as its disclosure would constitute unfair and unlawful processing and would be contrary to the principles and articles of the UK GDPR. This exemption is absolute and therefore, there is no requirement to apply the public interest test.

In reaching this decision, the DPA and UK GDPR define personal data as data that relates to a living individual who can be identified solely from that data or from that data and other information, which is in the possession of the data controller.

1. The UHB has treated one hundred and sixty (160) patients diagnosed with Multiple Myeloma, during the period 1 June to 30 November 2025.
2. The UHB provides within the table below, the number of patients diagnosed with Multiple Myeloma that were treated with each of the named treatments, as recorded on the ChemoCare system, during the period 1 June to 30 November 2025.

Treatments	Number
Any other systemic anti-cancer therapy	*
Belantamab Mafodotin [Blenrep]	*
Belantamab Mafodotin [Blenrep] with bortezomib and dexamethasone	0
Belantamab Mafodotin [Blenrep] with pomalidomide and dexamethasone	0
Bortezomib [Velcade] monotherapy or with dexamethasone	*
Bortezomib [Velcade], Melphalan/Cyclophosphamide and prednisolone/dexamethasone (VMp or VCd)	6
Bortezomib, thalidomide and dexamethasone [VTD]	0
Carfilzomib [Kyprolis] and dexamethasone	0
Carfilzomib [Kyprolis], Lenalidomide [Revlimid] and dexamethasone	7
Daratumumab [Darzalex] with Lenalidomide [Revlimid] and dexamethasone	23
Daratumumab [Darzalex] monotherapy	25

Daratumumab [Darzalex], Bortezomib [Velcade] and dexamethasone (known as DVd or DBd)	6
Daratumumab [Darzalex], Bortezomib [Velcade], thalidomide and dexamethasone (known as Dara-VTd)	17
Elranatamab	0
Idecabtagene vicleucel [Abecma]	0
Isatuximab [Sarclisa], Pomalidomide [Imnovid] and dexamethasone (known as IsaPd)	0
Ixazomib [Ninlaro], Lenalidomide [Revlimid] and dexamethasone (known as IRd)	9
Lenalidomide [Revlimid] and dexamethasone	6
Lenalidomide [Revlimid] monotherapy	20
Panobinostat in combination with Bortezomib and Dezamethasone	28
Pomalidomide [Imnovid] and dexamethasone	0
Selinexor and dexamethasone	*
Selinexor, Bortezomiv [Velcade] and dexamethasone	*
Talquetamab	*
Teclistamab [Tecvayli]	0
Total	160

3. The UHB provides within the table below, the number of patients initiated on the named treatments, as recorded on the ChemoCare system, during the period 1 June to 30 November 2025.

Treatments	Number
Bortezomib [Velcade] + Thalidomide + Dexamethasone (VTD)	0
Carfilzomib [Kyprolis] + Dexamethasone	0
Carfilzomib [Kyprolis] + Lenalidomide [Revlimid] + Dexamethasone (KRd)	*
Daratumumab [Darzalex] + Bortezomib [Velcade] + Dexamethasone (DVd/DBd)	11
Daratumumab [Darzalex] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Dara-VRd)	5
Daratumumab [Darzalex] + Bortezomib [Velcade] + Thalidomide + Dexamethasone (Dara-VTd)	5
Daratumumab [Darzalex] + Lenalidomide [Revlimid] + Dexamethasone (DRd)	10
Isatuximab [Sarclisa] + Bortezomib [Velcade] + Lenalidomide [Revlimid] + Dexamethasone (Isa-VRd)	0
Lenalidomide [Revlimid] monotherapy	0
Lenalidomide [Revlimid] + Dexamethasone	8
Selinexor + Bortezomib [Velcade] + Dexamethasone	*
Selinexor + Dexamethasone	*
Any other systemic anti-cancer therapy [please specify] - Cyclo PO monthly	*
Total	46

4. The UHB confirms that six (6) patients are recorded on the ChemoCare system as receiving the second-line treatment Lenalidomide [Revlimid] + Dexamethasone, during the period 1 June to 30 November 2025.